137 related articles for article (PubMed ID: 18791686)
41. Hepatitis C Virus Associations with Non Hodgkin's Lymphoma: Insights on Inflammation/Angiogenesis and CD Markers.
El-Maadawy EA; Talaat RM; Sadek RF; El-Sherbini SM; Abdel-Bary N; Abdel-Aziz AA
Asian Pac J Cancer Prev; 2016; 17(9):4415-4420. PubMed ID: 27797254
[TBL] [Abstract][Full Text] [Related]
42. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas.
Ren Y; Cao B; Law S; Xie Y; Lee PY; Cheung L; Chen Y; Huang X; Chan HM; Zhao P; Luk J; Vande Woude G; Wong J
Clin Cancer Res; 2005 Sep; 11(17):6190-7. PubMed ID: 16144920
[TBL] [Abstract][Full Text] [Related]
43. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.
Schmidt NO; Westphal M; Hagel C; Ergün S; Stavrou D; Rosen EM; Lamszus K
Int J Cancer; 1999 Feb; 84(1):10-8. PubMed ID: 9988225
[TBL] [Abstract][Full Text] [Related]
44. Elevated levels of angiogenic cytokines in the plasma of cancer patients.
Fuhrmann-Benzakein E; Ma MN; Rubbia-Brandt L; Mentha G; Ruefenacht D; Sappino AP; Pepper MS
Int J Cancer; 2000 Jan; 85(1):40-5. PubMed ID: 10585580
[TBL] [Abstract][Full Text] [Related]
45. Vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor-I and platelet-derived growth factor levels in human milk of mothers with term and preterm neonates.
Ozgurtas T; Aydin I; Turan O; Koc E; Hirfanoglu IM; Acikel CH; Akyol M; Erbil MK
Cytokine; 2010 May; 50(2):192-4. PubMed ID: 20202860
[TBL] [Abstract][Full Text] [Related]
46. Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis.
Bai Y; Bai L; Zhou J; Chen H; Zhang L
Cell Immunol; 2018 Jan; 323():19-32. PubMed ID: 29111157
[TBL] [Abstract][Full Text] [Related]
47. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
48. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.
Rueda A; Olmos D; Villareal V; Torres E; Pajares BI; Alba E
Clin Lymphoma Myeloma; 2007 May; 7(6):400-5. PubMed ID: 17621405
[TBL] [Abstract][Full Text] [Related]
49. Selected angiogenic cytokines in systemic lupus erythematosus patients.
Hrycek A; Janowska J; Cieślik P
Autoimmunity; 2009 Aug; 42(5):459-66. PubMed ID: 19811263
[TBL] [Abstract][Full Text] [Related]
50. Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin's lymphoma.
Toyama T; Ido A; Sasak H; Maeda K; Yamashita K; Kubuki Y; Suzuki M; Matsuoka H; Tsubouchi H
Oncol Rep; 2005 Mar; 13(3):439-44. PubMed ID: 15706413
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):316-21. PubMed ID: 12607599
[TBL] [Abstract][Full Text] [Related]
52. Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study.
Gray RT; O'Donnell ME; McGuigan JA; Spence GM
Br J Biomed Sci; 2012; 69(2):71-5. PubMed ID: 22872931
[TBL] [Abstract][Full Text] [Related]
53. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
54. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.
Praidou A; Klangas I; Papakonstantinou E; Androudi S; Georgiadis N; Karakiulakis G; Dimitrakos S
Curr Eye Res; 2009 Feb; 34(2):152-61. PubMed ID: 19219687
[TBL] [Abstract][Full Text] [Related]
55. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
56. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
Kim JG; Sohn SK; Kim DH; Baek JH; Lee NY; Suh JS; Chae SC; Lee KS; Lee KB
Leuk Lymphoma; 2005 Jun; 46(6):885-91. PubMed ID: 16019534
[TBL] [Abstract][Full Text] [Related]
57. Clinical correlations and prognostic relevance of tissue angiogenic factors in patients with gastric cancer.
Mohri Y; Miki C; Tanaka K; Kawamoto A; Ohi M; Yokoe T; Kusunoki M
Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):610-6. PubMed ID: 22130629
[TBL] [Abstract][Full Text] [Related]
58. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
59. [Investigation of mechanisms of action of growth factors of autologous platelet-rich plasma used to treat erectile dysfunction].
Epifanova MV; Chalyi ME; Krasnov AO
Urologiia; 2017 Sep; (4):46-48. PubMed ID: 28952692
[TBL] [Abstract][Full Text] [Related]
60. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
Edgren M; Lennernäs B; Larsson A; Kälkner KM
Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
